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Background: Evidence of an oseltamivir treatment 
effect on influenza A(H3N2) virus infections in hospi-
talised patients is incomplete. Aims: This cohort study 
aimed to evaluate risk factors for death among PCR-
confirmed hospitalised cases of seasonal influenza 
A(H3N2) of all ages and the impact of oseltamivir. 
Methods: Participants included all 332 PCR-confirmed 
influenza A(H3N2) cases diagnosed between 30 August 
2016 and 17 March 2017 in an English university teach-
ing Hospital. Oseltamivir treatment effect on odds of 
inpatient death was assessed by backward stepwise 
multivariable logistic regression analysis. Results: 
The odds of death were reduced by two thirds (odds 
ratio (OR): 0.32; 95% confidence interval (CI): 0.11–
0.93), in inpatients treated with a standard course of 
oseltamivir 75 mg two times daily for 5 days – com-
pared with those untreated with oseltamivir, after 
adjustment for age, sex, current excess alcohol intake, 
receipt of 2016/17 seasonal influenza vaccine, serum 
haemoglobin and hospital vs community attribution 
of acquisition of influenza. Conclusions: Oseltamivir 
treatment given according to National Institutes of 
Clinical Excellence (NICE); United States Centres for 
Disease Control and Prevention (CDC); Infectious 
Diseases Society of America (IDSA) and World Health 
Organization (WHO) guidelines was shown to be effec-
tive in reducing the odds of mortality in inpatients 
with PCR-confirmed seasonal influenza A(H3N2) after 
adjustment in a busy routine English hospital set-
ting. Our results highlight the importance of hospi-
tals complying with relevant guidelines for prompt 
seasonal influenza PCR testing and ensuring standard 
oseltamivir treatment to all PCR-confirmed cases of 
seasonal influenza.
Introduction
Seasonal influenza, which recurs annually in winter, 
remains a leading cause of morbidity and mortality 
worldwide and a major challenge to hospitals, which 
face severe pressures during this period of the year 
[1,2]. Hospitalisation and mortality from influenza dis-
proportionately affect the elderly [3-5], with the risk of 
mortality increasing with age over 65 years [6,7]. Other 
factors associated with mortality include underlying 
comorbidities [5,8], delay in presentation to medical 
care [8] and viral subtype, with infection with influenza 
A(H3N2) virus strains being of highest risk [3,5,7].
Circulating influenza virus strains and vaccine effective-
ness vary from season to season [9-11]. Understanding 
risk factors for poor outcome in seasonal influenza is 
therefore important in optimising the prevention and 
management of high-risk patients presenting to pri-
mary and secondary care and requires appropriately 
designed observational studies [9,12].
In common with many hospitals in the northern 
hemisphere winter of 2016/17, Cambridge University 
Hospitals (CUH) National Health Service (NHS) 
Foundation Trust was severely challenged by large 
numbers of patients admitted with influenza virus 
infection [13].
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During this season, influenza A(H3N2) virus strain pre-
dominated and seasonal influenza vaccine was esti-
mated to have moderate effectiveness of between 30% 
and 40% with lower levels of effectiveness in older 
patients [14-17].
Although recommended by several national and inter-
national agencies for the treatment of seasonal influ-
enza in patients requiring hospitalisation, including the 
National Institute for Health and Care Excellence (NICE) 
[18,19], the United States (US) Centers for Disease 
Control and Prevention (CDC) [20,21], the Infectious 
Disease Society of America (IDSA) [22] and the World 
Health Organization (WHO) [16], the evidence of an 
effect of oseltamivir on influenza-associated mortal-
ity in hospitalised patients is limited [10]. Randomised 
controlled trials (RCTs) have predominantly been under-
taken in outpatients and have indicated that oseltami-
vir reduced symptom duration and lower respiratory 
tract complications in otherwise healthy adults [23,24].
A retrospective cohort study was undertaken in our 
hospital of the clinical management of inpatients diag-
nosed by PCR with influenza A(H3N2) virus strain infec-
tion during the 2016/17 season to better understand 
risk factors for inpatient death and whether any effect 
of a standard course of oseltamivir 75 mg twice daily 
for 5 days was observed.
Methods
Institutional setting and approval
The CUH NHS Foundation Trust is a 1,100-bed univer-
sity teaching hospital providing district general hos-
pital services for Cambridgeshire and surrounding 
counties and specialised tertiary-level services across 
the East of England with a population of approximately 
six million.
Ethical statement
The study was registered with the Safety and Quality 
Support department of CUH NHS Foundation Trust 
under a Service Evaluation/Outbreak Investigation 
remit (Project Registration Number PRN 7053; 15 
January 2018).
Legal basis for processing personal identifying 
information
Processing and analysis of individual patient level data 
was undertaken in compliance with the General Data 
Protection Regulations [25,26].
Virological and bacteriological methods
A nose and a throat swab placed in a single tube of viral 
transport medium were collected from each patient. 
Detection of respiratory viruses was done by using a 
multiplex real-time PCR assay as described previously 
[27,28]. Bacteriology specimens were processed using 
standard Public Health England (PHE) methods.
Individuals considered in the study
Individuals in this study were patients of any age 
admitted to our hospital with a laboratory-confirmed 
diagnosis of influenza A(H3N2) virus strain infection, 
between 20 August 2016 and 17 March 2017. They were 
identified through our hospital laboratory information 
system (LIMS) and linked to electronic hospital medi-
cal record and general practitioner (GP) information 
systems. Death or discharge alive was recorded for the 
admission episode during which the virological swab 
testing positive for the influenza A(H3N2) virus strain 
was obtained.
Clinical data collection
Demographic and clinical details of the admission 
episode, date and time of admission, discharge, 
transfer and death, full blood count, blood chemis-
try, C-reactive protein, virology and bacteriology test 
results, oseltamivir prescriptions and receipt of sea-
sonal influenza vaccination were extracted from the 
electronic hospital medical record and GP information 
systems described earlier to a structured epidemiologi-
cal proforma.
Active medical conditions were recorded and the non-
age adjusted Charlson comorbidity index score cal-
culated [29]. Risk factors and conditions not included 
in the Charlson index were also recorded, comprising 
radiological evidence of pneumonia, current smoker, 
excessive alcohol use, admission with trauma, admis-
sion for surgery, pregnancy, hypertension, body 
mass index (BMI) ≥ 40 kg/m2  and receipt of respiratory 
support. Respiratory support was categorised as 
oxygen therapy, continuous positive airways pressure 
(CPAP), non-invasive ventilation (NIV) and invasive 
ventilation. Immune suppression was categorised as 
absent or present and, if present, categorised as: high 
dose steroids ≥ 40 mg of prednisolone daily or equiva-
lent; receiving or within 6 months of receiving chemo-
therapy or generalised radiotherapy, organ transplant 
or bone marrow transplant.
The clinical data abstraction proforma for oseltamivir 
exposure posed the question ‘was this patient pre-
scribed oseltamivir, yes or no? If yes, did this patient 
receive standard oseltamivir treatment 75 mg twice 
daily for 5 days, yes or no? If no, describe why not.’
The British National Formulary (BNF) standard course of 
oseltamivir for treatment of seasonal influenza is 75 mg 
twice daily for 5 days. For children modified doses are 
given according to body weight. Patients whose treat-
ment was completed according to this standard were 
categorised as standard course.
In renal failure the standard 5-day dose is reduced in 
adults to 30 mg twice daily if estimated glomerular fil-
tration rate (eGFR) is 30–60 mL/minute/1.73 m2  or to 
30 mg once daily if eGFR is 10–30 mL/minute/1.73 m2. 
In children this is 40% of normal dose for weight twice 
daily if eGFR is 30–60 mL/minute/1.73 m2  or 40% of 
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Table 1a
Analysis of single variables potentially associated with influenza A(H3N2) virus strain infection related deaths, Cambridge, 
England, 2016/17 (n = 332)
Variable Category or measure Expired Not expired OR (95% CI) p value
Age at positive specimen (years)
Minimum 34 0
1.04 (1.01–1.06) per year < 0.001
25th centile 71 53
Median 84 74
75th centile 88 85
Maximum 102 101
Sex
Female 13 162 Reference
0.15
Male 19 138 1.72 (0.82–3.60)
Body mass index (BMI) ≥ 40 Kg/m2
Yes 1 5 Reference
0.6
No 31 295 1.90 (0.22–16.8)
Pregnancy
Pregnant 0 3 0.00 (not estimable)
0.3Not pregnant 13 159 Reference
Male 19 138 1.68 (0.80–3.54)
Oseltamivir course completed
1. Not given 7 66 Reference
0.7
2. Non-standard course 3 18 1.57 (0.37–6.70)
3. Appropriately modified 6 40 1.41 (0.44–4.51)
4. Standard course 16 176 0.86 (0.34–2.18)
Days between onset of influenza illness and first 
dose of oseltamivir
Minimum 0 0
0.89 (0.74–1.06) per day delay 0.4
25th centile 2 2
Median 3 3
75th centile 5 5
Maximum 11 18
Current smoker
Yes 2 29 0.60 (0.13–2.68)
0.5
No 23 200 Reference
Long-term oxygen therapy
Yes 1 2 4.69 (0.41–53.6)
0.3
No 24 225 Reference
Hypertension
Yes 14 111 1.32 (0.63–2.77)
0.5
No 18 189 Reference
Trauma
Yes 1 4 2.39 (0.26–22.0)
0.5
No 31 296 Reference
Excessive alcohol use
Yes 3 5 6.10 (1.39–26.8)
0.03
No 29 295 Reference
Surgery
Yes 3 13 2.28 (0.61–8.48)
0.25
No 29 287 Reference
Immune suppressed
Yes 3 61 0.40 (0.12–1.37)
0.11
No 29 238 Reference
Receipt of 2016/17 influenza vaccine
Yes 11 110 0.90 (0.42–1.95)
0.8
No 21 190 Reference
Steroids
Yes 0 2 0.00 (not estimable)
0.5
No 32 298 Reference
Chemotherapy
Yes 0 21 0.00 (not estimable)
0.04
No 32 279 Reference
Radiotherapy
Yes 1 1 9.65 (0.59–158)
0.14
No 31 299 Reference
Organ transplant
Yes 0 12 0.00 (not estimable)
0.12
No 32 288 Reference
Bone marrow transplant
Yes 0 4 0.00 (not estimable)
0.4
No 32 296 Reference
Immune deficiency syndrome
Yes 0 0 Not estimable
NA
No 32 300 Reference
Other category of immune suppression
Yes 2 21 0.89 (0.20–3.96)
0.9
No 30 279 Reference
OR: odds ratio; CI: confidence interval; QF: quadratic function; NA: not applicable.
.
4 www.eurosurveillance.org
OR: odds ratio; CI: confidence interval; QF: quadratic function; NA: not applicable.
a QF: linear part OR: 1.28 (95% CI: 1.11–1.47); quadratic part OR: 1.00 (95% CI: 0.99–1.00).
b QF: linear part OR: 1.05 (95% CI: 1.01–1.09); quadratic part OR: 1.00 (95% CI: 1.00–1.00).
c QF: linear part OR: 2.45 (95% CI: 1.48–4.06); quadratic part OR: 0.97 (95% CI: 0.94–0.99).
Table 2a
Analysis of single variables potentially associated with influenza A(H3N2) virus strain infection related deaths, Cambridge, 
England, 2016/17 (n = 332)
Variable Category or measure Expired Not expired OR (95% CI) p value
Haemoglobin concentration g/L
Minimum 68 45
0.98 (0.96–0.99) per g/L 0.01
25th centile 98.5 108
Median 112 123
75th centile 124 135
Maximum 153 175
Total white cell count × 109/L
Minimum 2.1 0
QFa 0.008
25th centile 7.7 5.3
Median 10.1 7.3
75th centile 14.3 9.6
Maximum 48.5 53.6
Lymphocyte count × 109/L
Minimum 0.2 0
0.88 (0.57–1.37) per count per × 
109/L 0.4
25th centile 0.5 0.5
Median 0.8 0.8
75th centile 1.2 1.2
Maximum 2.3 46.7
C-reactive protein mg/L
Minimum 5 1
1.00 (1.00–1.01) 0.01
25th centile 26.3 19.6
Median 64.9 39.9
75th centile 164 76.6
Maximum 431 479
Creatinine mmol/L
Minimum 48 8
QFb 0.002
25th centile 69 64
Median 99 84
75th centile 114 111
Maximum 187 742
Urea mmol/L
Minimum 4.5 1.6
QFc < 0.001
25th centile 7.2 4.6
Median 9.2 6.2
75th centile 11 8.6
Maximum 18.6 39.2
Glucose mmol/L
Minimum 5.1 3.4
1.04 (0.95–1.13) per mmol/L 0.4
25th centile 6.7 6
Median 7.8 6.9
75th centile 8.9 8.7
Maximum 24 36.2
Required oxygen
Yes 8 32 2.79 (1.16–6.73)
0.03
No 24 268 Reference
Continuous positive airways pressure
Yes 1 3 3.20 (0.32–31.6)
0.4
No 31 297 Reference
Non-invasive ventilation
Yes 3 3 10.2 (1.98–53.1)
0.01
No 29 297 Reference
Invasive ventilation
Yes 5 22 2.34 (0.82–6.68)
0.14
No 27 278 Reference
Charlson comorbidity index
Minimum 0 0
1.21 (1.03–1.43) 0.03
25th centile 2 1
Median 2 2
75th centile 4 3
Maximum 8 10
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Table 3a
Analysis of single variables potentially associated with influenza A(H3N2) virus strain infection related deaths, Cambridge, 
England, 2016/17 (n = 332)
Variable Category or measure Expired Not expired OR (95% CI) p value
Cycle threshold (CT) 
 
value
Minimum 19 16
0.96 (0.88–1.04) 0.3
25th centile 23 27
Median 27 30
75th centile 32 32
Maximum 38 41
Place of acquisition of infection
Community 15 219 Reference
0.003
Hospital 17 81 3.06 (1.46–6.42)
Admitted from
Own home 25 251 Reference
0.5
Residential care 4 28 1.43 (0.47–4.42)
Another hospital 3 13 2.32 (0.62–8.68)
Other 0 4 0.00 (not estimable)
Oseltamivir prescribed for post-exposure 
prophylaxis
Yes 2 8 2.43 (0.49–12.0)
0.3
No 30 292 Reference
Pneumonia
No imaging 2 34 Reference
0.005No pneumonia on image 16 214 1.27 (0.28–5.78)
Pneumonia on image 14 52 4.58 (0.98–21.4)
Myocardial infarction
Yes 6 32 1.93 (0.74–5.05)
0.2
No 26 268 Reference
Congestive heart failure
Yes 5 33 1.50 (0.54–4.16)
0.5
No 27 267 Reference
Peripheral vascular disease
Yes 3 8 3.78 (0.95–15.0)
0.09
No 29 292 Reference
Cerebro vascular disease
Yes 8 47 1.79 (0.76–4.23)
0.2
No 24 253 Reference
Dementia
Yes 8 38 2.30 (0.96–5.48)
0.08
No 24 262 Reference
Chronic lung disease
Yes 16 88 2.41 (1.15–5.03)
0.02
No 16 212 Reference
Connective tissue disease
Yes 2 21 0.89 (0.20–3.96)
0.9
No 30 279 Reference
Peptic ulcer
Yes 3 6 5.07 (1.20–21.3)
0.047
No 29 294 Reference
Mild liver disease
Yes 1 2 4.81 (0.42–54.5)
0.3
No 31 298 Reference
Moderate or severe liver disease
Yes 3 9 3.34 (0.86–13.0)
0.11
No 29 291 Reference
Diabetes without end organ damage
Yes 5 49 0.95 (0.35–2.58)
0.9
No 27 251 Reference
Diabetes with end organ damage
Yes 2 15 1.27 (0.28–5.81)
0.8
No 30 285 Reference
Hemiplegia
Yes 1 13 0.71 (0.09–5.63)
0.7
No 31 287 Reference
Moderate or severe kidney disease
Yes 5 46 1.02 (0.37–2.79)
0.97
No 27 254 Reference
Tumour without metastasis
Yes 3 22 1.31 (0.37–4.63)
0.7
No 29 278 Reference
Tumour with metastasis
Yes 1 6 1.58 (0.18–13.6)
0.7
No 31 294 Reference
Leukaemia
Yes 0 11 0.00 (not estimable)
0.13
No 32 289 Reference
Lymphoma
Yes 0 16 0.00 (not estimable)
0.07
No 32 284 Reference
OR: odds ratio; CI: confidence interval; QF: quadratic function; NA: not applicable.
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normal dose by weight once daily if eGFR is 10–30 mL/
minute/1.73 m2. In patients with immune suppression 
the standard course is extended from 5 to 10 days. 
Patients whose treatment was modified for renal fail-
ure or immune suppression in accordance with the BNF 
were categorised as having received an appropriately 
modified standard course.
Cases whose oseltamivir treatment was neither stand-
ard, 75 mg twice daily for 5 days, nor appropriately 
modified, were categorised as having received a non-
standard course of oseltamivir.
Oseltamivir exposure was categorised from these 
responses as not received (category 1); received a 
non-standard course (category 2); received an appro-
priately modified course (category 3); or received a 
standard course 75 mg twice daily for 5 days (cate-
gory 4) compared with the BNF [30]. Time of starting 
oseltamivir was calculated from the date of onset of 
influenza symptoms to the date of the first dose given 
in the pharmacy record, which is part of the electronic 
patient record.
Alcohol exposure was obtained from a table enti-
tled ‘active conditions on admission’ which sought a 
response for the item ‘Excessive alcohol use’ yes or no.
Hospital and primary care records were reviewed for 
evidence of having received an NHS approved seasonal 
influenza vaccine for the 2016/17 influenza season. 
The clinical data abstraction questionnaire field read 
‘Record of receipt of an NHS approved 16/17 seasonal 
influenza vaccine? yes or no.’
The place of acquisition of influenza A(H3N2) virus 
strain infection was attributed to the community when 
symptom onset was before admission or within 2 days 
of admission and if no outpatient contact with the 
hospital had occurred within 2 days of onset of symp-
toms. Hospital acquisition was attributed where onset 
of symptoms was more than 2 days after admission or 
if outpatient, dialysis or chemotherapy day centre con-
tact at our hospital had occurred within 2 days of onset 
of influenza illness.
Statistical analysis
Statistical analysis was undertaken in STATA15.1. using 
single variable and multivariable regression methods 
[31]. Single variable analysis associations between 
inpatient death and individual risk factors, including 
the individual components of the Charlson comorbid-
ity index and the non-age adjusted Charlson comorbid-
ity index, were examined by logistic regression using 
likelihood ratio tests (LRT) and p values and odds 
ratios (OR) and 95% confidence intervals (CI) deter-
mined. Variables with p < 0.2 by LRT in the single vari-
able analysis and sex were considered in the stepwise 
multivariable logistic regression analysis. Appropriate 
functional forms for continuous variables were deter-
mined by successively fitting cubic, quadratic and lin-
ear functions and selecting the simplest for which no 
improvement in fit was observed by LRT in both single 
and multivariable analyses.
The initial model consisted of sex and variables with 
p ≤ 0.01 by LRT from the single variable analysis. A 
backwards stepwise procedure was undertaken drop-
ping non-confounding variables with the largest LRT 
p > 0.1 one at a time. A variable was judged to be con-
founding if its omission resulted in a change of more 
than 20% in the OR in one or more of the parameters 
still in the model. The process continued until no fur-
ther variables could be removed.
Variables with p ≤ 0.1 in the single variable analysis 
were then added in a forward procedure and the above 
procedure repeated, at the end of which the remaining 
variables with p > 0.1 were added and the backwards 
stepwise procedure implemented.
The variables for the category of oseltamivir treatment 
completed and receipt of 2016/17 seasonal influenza 
vaccine were then added to the model. Following this, 
variables which had been dropped from the model 
were again added singly and then removed before add-
ing another to check that they should still be omitted. 
Variables found to be substantial confounders were 
then added to the model. The appropriate functions of 
the continuous variables still in the model were again 
determined to give the final multivariable model of risk 
factors independently associated with inpatient death, 
adjusting for the category of oseltamivir treatment 
received and receipt of an NHS approved 2016/17 sea-
sonal influenza vaccine.
A second multivariable model was fitted replacing the 
variable for the category of oseltamivir treatment with 
the variable for the delay between the date of onset of 
influenza illness and the date of commencing oseltami-
vir treatment.
Interactions
Interaction terms were tested between the categories 
of oseltamivir treatment received, delay in receipt of 
oseltamivir, receipt of approved 2016/17 seasonal 
influenza vaccine and if immune suppressed. The vari-
able of the delay was considered in two two-way inter-
actions, one being with the receipt of seasonal vaccine 
and the other immune suppressed. The two-way inter-
action between immune suppression and seasonal 
vaccine receipt and the three-way interaction between 
delay, seasonal vaccine receipt and immune suppres-
sion were tested. These interactions were considered 
in both the single and multivariable analysis.
Results
Single variable analysis
The cohort comprised 332 patients with a mean age 
of 68.6 years (range: 0–102) of whom 175 (52.7%) were 
female. A total of 32 (9.6%) of these patients died 
during admission (Table 1). The time from admission 
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to death, discharge or transfer to other hospitals was 
median 7 days (interquartile range: 3–23). Eight (2.4%) 
patients were aged under 18 years: one under 1 year; 
three aged 2 years; one aged 5 years; one aged 8 years; 
and two aged 17 years, none of whom expired dur-
ing admission. Twenty-six (8.1%) of the patients were 
admitted to an intensive care unit (ICU).
Oseltamivir was not prescribed for 73 of the 332 (22%) 
of patients. Among these patients, the reasons for not 
having been prescribed oseltamivir were because more 
than 48 hours had elapsed since onset of symptoms 
(n = 10; 13.7%), discharged before the positive PCR test 
result for influenza A(H3N2) virus strain was available 
(n = 18; 24.7%), clinically improved (n = 8; 11%), died 
before the test result was received (n = 2; 2.7%), drugs 
stopped for palliative care (n = 1; 1.4%), and no reason 
given (n = 34; 46.6%). No patients were detected as 
having received oseltamivir before admission.
Significantly raised odds (p < 0.05) for inpatient death 
were observed for age (OR: 1.04; 95% CI: 1.01–1.06) 
per year, Charlson comorbidity index (OR: 1.21; 
95% CI: 1.03–1.43) per unit, excessive alcohol use 
(OR: 6.10; 95% CI: 1.39–26.8), peptic ulcer (OR: 5.07; 
95% CI: 1.2–21.3), radiological evidence of pneumonia 
(OR: 4.58; 95% CI: 0.98–21.4), requirement for oxygen 
therapy (OR: 2.79; 95% CI: 1.16–6.73) and receipt of 
non-invasive ventilation (OR: 10.2; 95% CI: 1.98–53.1). 
Acquisition of infection within hospital compared 
with community was also associated with raised odds 
(OR: 3.06; 95% CI: 1.46–6.42).
Completion of a standard course of oseltamivir 75 mg 
two times daily for 5 days compared with no treatment 
with oseltamivir showed a non-significant protective 
effect (OR: 0.86; 95% CI: 0.34–2.18). No protection 
was observed for non-standard courses of oseltamivir 
(OR: 1.57; 95% CI: 0.37–6.70) or appropriately modified 
course consistent with the BNF (OR: 1.41; 95% CI: 0.44–
4.51). No significant association was seen for delay 
starting oseltamivir (OR: 0.89; 95% CI: 0.74–1.06), with 
having received the 2016/17 seasonal influenza vaccine 
(OR: 0.90; 95% CI: 0.42–1.95) or with being immune 
suppressed (OR: 0.40; 95% CI: 0.12–37).
The significance of interaction terms were delay in 
starting oseltamivir and 2016/17 seasonal influenza 
vaccine p = 0.14, delay and immune suppression p = 0.7, 
immune suppression and seasonal influenza vaccine 
p = 0.2, and delay in starting oseltamivir and immune 
supressed and seasonal influenza vaccine p > 0.999.
Six patients, all of whom survived, were confirmed 
to have bacterial infection synergistic with influenza 
A(H3N2) virus strain infection by positive cultures 
for  Streptococcus pneumoniae  or  Haemophilus influ-
enzae  in blood or sputum. None of the patients who 
expired had evidence of synergistic bacterial infection 
with influenza A(H3N2) virus strain infection.
Multivariable analysis
The variables age, sex, place of acquisition, serum 
haemoglobin concentration, excessive alcohol use, 
category of oseltamivir course completed and receipt 
of 2016/17 seasonal influenza vaccine met the criteria 
for inclusion in the final multivariable model (Table 2).
Cases who received a BNF standard course of oseltami-
vir of 75 mg two times daily for 5 days were significantly 
Table 2
Final multivariable analysis of variables independently associated with inpatient death, Cambridge, England, 2016/17 
(n = 329)a
Variable Category OR (95% CI) p value
Age NA 1.06 per year (1.03–1.10) < 0.001
Sex
Female Reference
0.19
Male 1.73 (0.76–1.94)
Place of acquisition
Community Reference
0.16
Hospital 1.82 (0.79–4.23)
Haemoglobin concentration g/L NA 0.97 (0.95–1.00) per g/L 0.02
Excessive alcohol use
Yes 13.2 (1.93–90.5)
0.01
No Reference
Oseltamivir course completed
1.Not given Reference
0.23
2. Non-standard course 0.3 (0.06–1.54)
3. Appropriately modified course 0.34 (0.09–1.28)
4. Standard course 0.32 (0.11–0.93)
Receipt of 2016/17 seasonal influenza vaccine
Yes 0.63 (0.26–1.49)
0.3
No Reference
CI: confidence interval; NA: not applicable; OR: odds ratio.
a Of 332 patients, 329 had serum haemoglobin concentration results.
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protected against death compared with those not given 
oseltamivir (OR: 0.32; 95% CI: 0.11–0.93) A protective 
though non-significant association was also observed 
for receipt of a non-standard course of oseltamivir 
(OR: 0.3; 95% CI: 0.06–1.54) and a BNF appropriately 
modified course of oseltamivir (OR: 0.34; 95% CI: 0.09–
1.28). Receipt of the 2016/17 seasonal influenza 
vaccine was not significantly protective (OR: 0.63; 
95% CI: 0.29–1.49).
History of excessive alcohol use was associated with 
a 13-fold (OR: 13.2; 95% CI: 1.93–90.5) higher odds of 
death. Higher serum haemoglobin was significantly 
protective (OR:  0.97; 95% CI: 0.95–1.00) per gram 
per litre. Males and those whose acquisition of infec-
tion was in hospital had non-significantly raised odds 
(OR: 1.73; 95% CI: 0.76–1.94 and OR: 1.82; 95% CI: 0.79–
4.23 respectively).
In a second multivariable model, the category of 
oseltamivir course received was replaced by the 
delay in days between onset date and starting date 
of oseltamivir treatment (Table 3). This delay was not 
significantly associated with inpatient death (OR: 0.92; 
95% CI: 0.77–1.09). The remaining variables had similar 
odds as in the first multivariable model Tables 2 and 3.
None of the following interactions tested in the model 
shown in Table 3 reached statistical significance: delay 
in starting oseltamivir and receipt of 2016/17 seasonal 
influenza vaccine p = 0.6, delay and immune sup-
pressed p = 0.6, immune suppressed and receipt of 
2016/17 seasonal influenza vaccine p = 0.3, and delay 
and immune suppressed and receipt of 2016/17 sea-
sonal influenza vaccine p > 0.999.
Variables significantly associated with raised odds in 
single variable analysis p< 0.05 (Table 1) but excluded 
in our multivariable model building (Tables 2  and  3) 
were chemotherapy, total white cell count, serum 
C-reactive protein, serum creatinine, serum urea, sup-
plementary oxygen therapy, non-invasive ventilation, 
Charlson comorbidity index, radiological evidence of 
pneumonia, chronic lung disease, and peptic ulcer.
Discussion
This study of a large cohort of laboratory-confirmed 
seasonal influenza A (H3N2) cases admitted to a United 
Kingdom (UK) NHS hospital measured the odds of all-
cause inpatient mortality. Our study has chronicled the 
effectiveness of oseltamivir in reducing inpatient mor-
tality in a hospital typical of the UK NHS in winter sea-
son 2016/17 for the influenza A(H3N2) virus strain and 
that a proportion of patients had not received oseltami-
vir treatment at standard BNF dose according to NICE 
and WHO guidelines for several operational reasons, 
some of which were amenable to improvement.
While RCTs of oseltamivir treatment of influenza virus 
infection have been conducted in outpatients, there 
are currently no completed placebo-controlled RCTs of 
oseltamivir for treatment of influenza in hospitalised 
patients, thus the need for observational studies [10].
The need for observational studies to supplement RCTs 
is recognised [9] and can provide up to date measures 
of effectiveness of interventions and treatments in 
routine clinical settings with external validity. This is 
important in seasonal influenza where the effective-
ness of vaccines and the virulence of circulating influ-
enza virus strains vary over time [10,11].
We identified clinical parameters in single variable 
analysis recognised as risk factors for poor outcome 
including elevated total white cell count and C-reactive 
protein, pneumonia, and the need for supplementary 
oxygen and ventilation [32], but these did not meet our 
inclusion criteria for our final multivariable models.
Table 3
Multivariable analysis with delay in days between symptom onset and start of oseltamivir treatment, Cambridge, England, 
2016/17 (n = 299)a
Variable Category OR (95% CI) p value
Age NA 1.06 per year (1.03–1.10) < 0.001
Sex
Female Reference
0.19
Male 1.74 (0.75–4.01)
Place of acquisition
Community Reference
0.4
Hospital 1.43 (0.57–3.58)
Haemoglobin concentration g/L NA 0.97 (0.95–0.99) per g/L 0.01
Excessive alcohol use
Yes 16.7 (1.77–156)
0.02
No Reference
Time delay from onset of symptoms to starting oseltamivir in days NA 0.92 per day (0.77–1.09) 0.1
Receipt of 2016/17 seasonal influenza vaccine
Yes 0.59 (0.25–1.40)
0.22
No Reference
CI: confidence interval; NA: not applicable; OR: odds ratio.
a Of 332 patients, 299 had information on time delay and haemoglobin concentration.
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The variables meeting our selection criteria for our final 
multivariable model (Table 2) were age, sex, place of 
acquisition, serum haemoglobin concentration, exces-
sive alcohol use, category of oseltamivir treatment and 
receipt of 2016/17 seasonal influenza vaccine.
The significant independent protective association 
against inpatient death of higher serum haemoglobin 
concentration is consistent with this being a marker of 
good general nutrition and better health [33]. Excessive 
alcohol use emerged as a major confounder and may 
be explained at least in part, by its association with 
severe liver disease, which is a well-recognised risk 
factor for severe influenza virus infection. We com-
bined moderate and severe liver disease as a single 
variable as required for the Charlson comorbidity index 
but this was not associated with raised odds of inpa-
tient death in our single variable analysis (Table 1).
Recorded receipt of 2016/17 seasonal influenza vaccine 
neither protected our cases from infection with influ-
enza (A(H3N2) virus strain nor modified the protec-
tive effect of oseltamivir on inpatient death as shown 
by the non-significance of its interaction terms. These 
results are in keeping with the observed poor effective-
ness of the vaccine against influenza A(H3N2) particu-
larly in the elderly [14,15,17].
The effectiveness of oseltamivir in the prevention and 
treatment of seasonal and pandemic influenza remains 
a subject of debate [34-36].
Acceptance of the protective effect of oseltamivir 
against inpatient mortality in seasonal influenza 
A(H3N2) virus strain infection shown in our study, 
may be perceived to be at variance with meta-analy-
ses of RCTs, which have concluded that the benefits 
of oseltamivir treatment are confined to shortening of 
influenza symptoms [23,24,37,38]. However, these tri-
als have been done in outpatients and almost exclu-
sively in younger adults with no comorbidities and 
are probably not generalisable to the largely elderly 
hospitalised population in this study [9,39] for whom 
oseltamivir treatment is recommended by NICE, IDSA, 
CDC and WHO [16,18,19,22,40]. Our findings concur 
with meta-analyses of observational studies conclud-
ing a protective effect of oseltamivir on mortality in 
patients hospitalised with Influenza [41,42]. However, 
Jones and Wolkewitz have raised concerns about the 
meta-analysis by Muthuri et al. on handling of time-
dependent treatment and the absence of follow up 
beyond hospital discharge [43,44].
In keeping with previous observational studies [42,45], 
we found no evidence to support the notion that the 
protective benefit of oseltamivir was limited in this 
high-risk population to within 48 hours after the onset 
of symptoms. The additional benefit found in our cohort 
may reflect the higher proportions of elderly and immu-
nocompromised patients who have longer times from 
symptom onset to cessation of viral replication [46,47].
The failure to give oseltamivir treatment to cases of 
influenza A (H3N2) virus strain admitted to hospital 
may expose cases to an avoidable threefold higher 
odds of inpatient mortality than would have been the 
case had they been treated and as recommended by 
national and international guidance. Infection ascribed 
to being acquired in hospital as compared to being 
acquired in the community met our selection crite-
ria for inclusion in our final multivariable models and 
weak but non-significant association with raised odds 
of inpatient mortality was seen. This may be explained 
by greater comorbidity in the former group of patients.
We measured the odds of inpatient mortality as our 
outcome using logistic regression and showed a pro-
tective effect of oseltamivir treatment in hospital-
ised patients. Our conclusion of a protective effect of 
oseltamivir against inpatient mortality in hospitalised 
patients is congruent with the conclusion of a recent 
systematic review of systematic reviews [36].
Our conclusions contrast with studies measuring dura-
tion of admission as well as inpatient mortality using 
survival analysis. A case for modelling discharge from 
the population at risk as a competing hazard for death 
during admission has been made [44,48]. Multistate 
models were used comprising hospital admission, 
oseltamivir treatment, discharge, and death timed 
from onset of influenza symptoms using 1,391 case 
records of confirmed pandemic influenza A(H1N1) virus 
strain infection collected during 2009 and 2010 in the 
UK by the UK Flu collaboration [48,49]. A corrected 
hazard ratio (HR) of death in hospital associated with 
oseltamivir treatment was found to be non-significant 
(HR: 1.03; 95% CI: 0.64–1.66) but significant for dis-
charge (HR: 1.89; 95% CI: 1.65–2.16). Lytras et al. mod-
elled discharge from ICUs alive as a competing hazard 
for death within the ICUs, for oseltamivir exposure 
dichotomised to early (≤ 48 hours after onset) vs later 
(> 48 hours) for influenza A(H3N2) virus strain infec-
tion in a cohort of 1,330 patients admitted to ICUs in 
Greece over eight influenza seasons between 2010 and 
2018 [50]. Although early treatment with oseltamivir 
was associated with significantly lower mortality (rela-
tive risk (RR): 0.69; 95% CI:  0.49–0.94), the authors 
ascribed this effect purely to increased cause-specific 
hazard for discharge.
The absence of demonstrable protective effect of 
oseltamivir on inpatient mortality in these studies 
contrast to our results. This could be explained by the 
differences in the influenza A virus strains being stud-
ied; treating discharge from the population at risk as a 
competing hazard with patient death rather than con-
sidering death alone as the outcome; and differences 
in adjustment for confounding. For example, no adjust-
ment was made for excessive alcohol use in these 
studies, while we observed excessive alcohol use to be 
a significant confounder of the relationship between 
seasonal influenza A(H3N2) virus strain infection and 
inpatient death.
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Limitations
Our study was limited by being for a single season 
from a single hospital and for cases only infected by 
influenza A(H3N2) virus strain. We enrolled all influ-
enza A(H3N2) virus strain positive patients to our 
study cohort, but it is possible that some cases may 
still have been missed from viral swabbing. The small 
proportion of children we recruited may reflect this. 
Because we had few children aged under 18 years, we 
were unable to draw specific conclusions on this age 
group. It is possible that we may not have recorded 
fully oseltamivir given before admission to hospital, 
but we think this is unlikely because data abstrac-
tors were clinicians reviewing the entire clinical record 
including drugs given before admission and primary 
care physician referral letters and with a study remit to 
search for reasons why a completed standard course of 
oseltamivir had not been given. No case of oseltamivir 
having been given before admission was reported.
It is possible that a further proportion of our patients 
had received seasonal influenza vaccine than we 
recorded, because influenza vaccination is offered in 
pharmacies and supermarkets from which vaccination 
records may not have been completely transferred to 
the primary care records which we used. We do not 
think this would have led to a major impact on our con-
clusions because we did not detect a protective effect 
for seasonal influenza vaccination alone or as an inter-
action term with oseltamivir, and because the 2016/17 
influenza vaccine was of low effectiveness particularly 
in the elderly [14]. Corroboration of our results in future 
seasons in other centres and for other virus strains of 
seasonal influenza is desirable.
Conclusions
Standard oseltamivir treatment of 75 mg twice daily for 
5 days was shown to be effective in reducing the odds 
of inpatient mortality by two thirds (OR: 0.32; 95% CI: 
0.11–0.93) in patients hospitalised with PCR-confirmed 
seasonal influenza A(H3N2) virus strain infection in a 
routine NHS setting.
Rapid treatment with oseltamivir requires rapid diag-
nosis of seasonal influenza virus infections and this 
means hospitals must ensure routine use of influenza 
molecular assays with high sensitivity and specificity 
as recommended by NICE, CDC and IDSA.
Consideration should be given to revising current NICE 
and PHE guidelines for hospitalised patients diagnosed 
with seasonal influenza virus infection that oseltamivir 
should be started within 48 hours of onset of influenza 
symptoms, to align them with CDC and IDSA guide-
lines, which recommend that oseltamivir treatment for 
confirmed and suspected hospitalised influenza cases 
should be started on oseltamivir treatment 75 mg twice 
daily for 5 days regardless of the duration of influenza 
illness before hospitalisation .
As new antivirals for influenza viruses are developed, 
further studies will be required to determine their effec-
tiveness in high-risk patients and inpatient settings.
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